At Kezar Life Sciences, we are developing first-in-class, small molecule therapies designed to inhibit multiple disease-driving cellular pathways by targeting key intracellular proteins. Leveraging our team’s unmatched scientific expertise in target biology and medicinal chemistry, we are advancing two differentiated therapeutic approaches: Selective Immunoproteasome Inhibition, for the treatment of autoimmune diseases through immune modulation versus direct immunosuppression; and Protein Secretion Inhibition, halting the secretion of target proteins that contribute to a range of cancers and autoimmune diseases.

Since inception, our mission has been to deliver unique treatments that can better the lives of patients fighting difficult-to-treat chronic diseases. Our team is passionate about discovering promising targets that were previously unidentified or undruggable and have the potential to change the treatment paradigm for a range of conditions.